Showing results (521-530 of 868) with videos related to
Sort By:
Pageof 87
ACS Applied Materials & Interfaces|November 22, 2022
Highly Stable Hierarchically Structured All-Polymeric Lubricant-Infused Films Prevent Thrombosis and Repel Multidrug-Resistant PathogensElisabet Afonso, Fereshteh Bayat, Liane Ladouceur, et al.Thrombosis and Haemostasis|May 6, 2020
Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active CancerMichela Giustozzi, Antonio Curcio, Bob Weijs, et al.Journal of Thrombosis and Haemostasis : JTH|March 6, 2026
Antibody BAY3018250 against antiplasmin enhances plasminogen activation in vitro and thrombolysis in rabbitsC J Lindo, Peng Liao, Alina Khan, et al.Thrombosis and Haemostasis|March 29, 2019
Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort StudyThalia S Field, Bob Weijs, Antonio Curcio, et al.Scientific Reports|February 23, 2019
Identification and characterization of a factor Va-binding site on human prothrombin fragment 2Alexander P Friedmann, Anatoli Koutychenko, Chengliang Wu, et al.BMC Biochemistry|March 19, 2013
The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligandAmanda J Boyle, Leigh Ann Roddick, Varsha Bhakta, et al.Journal of Thrombosis and Haemostasis : JTH|July 23, 2025
Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trialLynn Malec, Mary Mathias, Amy L Dunn, et al.Blood|May 11, 2006
The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer sizeJeffrey I Zwicker, Flora Peyvandi, Roberta Palla, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|October 10, 2025
Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half-Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective StudyLuigi Piero Solimeno, Roberta Gualtierotti, Emanuele Guido, et al.Thrombosis and Haemostasis|August 15, 2015
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico studyStefano Lancellotti, Flora Peyvandi, Maria Teresa Pagliari, et al.Pageof 87